Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Promises ‘Competitive’ Clinical Trial Process Whatever The Brexit Outcome

Executive Summary

The UK pharmaceutical industry has welcomed government guidance on the clinical trial regulatory landscape after Brexit, as well as a report from Cancer Research UK on the need to preserve alignment with the EU’s Clinical Trial Regulation.

Related Content

UK Smooths Clinical Trial Pathway To Reassure Companies With Brexit Jitters
No Brexit Fall Out For UK FIH Trials With Over 40% Jump In Applications
UK Regulatory Changes During A Brexit Transition Period – The Government Explains All





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts